A potential role for GPR160 and its ligand, CART, in the modulation of feeding behavior in Prader-Willi Syndrome

Abstract

Hyperphagia is a hallmark of Prader-Willi syndrome (PWS). Managing the extreme hunger and insatiability associated with PWS remains a considerable challenge to PWS patients and their caregivers. Appetite and feeding behavior are governed by numerous neural circuits, several of which are potentially disrupted when some or all of the Prader-Willi critical region on chromosome 15 is lost. Previous research has focused on well-established feeding circuits in an effort to uncover the physiology underlying PWS hyperphagic behavior; however, due to the complex interplay between these circuits, much is left to be explored. We have previously demonstrated that interactions between GPR160 and its ligand cocaine and amphetamine regulated transcript (CART) are important in the control of feeding behavior. Several groups have reported that CART exerts anorexigenic properties when injected into areas of the brain that are important to feeding behavior, including regions of the brainstem and hypothalamus. The prohormone convertase PSCK1, which is responsible for post-translational processing of the CART prohormone, appears to be reduced in PWS patients, suggesting that CART could play a role in the pathophysiology of PWS. Using a rat model of PWS supplied by the Foundation for Prader-Willi Research (Magel2- deficient), we seek to investigate this potential role of CART and GPR160 in PWS-associated hyperphagia. Through the use of continuous monitoring of food and water intake, we were able to define meal patterning differences between wild type and paternally Magel2-deficient rats. In addition to evaluating baseline meal patterning, we also administered CART centrally and recorded CART-induced changes in feeding behavior. Lastly, we determined physiologic changes in levels of GPR160, CART, and PSCK1 in the pituitary, hypothalamus, amygdala, and brainstem from WT and paternally-deficient Magel2 rats in the setting of metabolic stress (fasting). Although additional studies must be performed to better define the role of CART and GPR160 in the feeding behavior of PWS patients, we anticipate that this ligand-receptor pair has the potential to serve as a novel therapeutic target for the treatment of PWS-associated hyperphagia. Foundation for Prader-Willi Research This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.